FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.

Samms RJ, Cheng CC, Fourcaudot M, Heikkinen S, Khattab A, Adams J, Cersosimo E, Triplitt C, Puckett C, Tsintzas K, Adams AC, Abdul-Ghani MA, DeFronzo RA, Norton L

Open source

DOI: 10.1152/ajpendo.00050.2022
Published: 2022 Aug 1
Container: American journal of physiology. Endocrinology and metabolism
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1152/ajpendo.00050.2022,
  title = {FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.},
  author = {Samms RJ and Cheng CC and Fourcaudot M and Heikkinen S and Khattab A and Adams J and Cersosimo E and Triplitt C and Puckett C and Tsintzas K and Adams AC and Abdul-Ghani MA and DeFronzo RA and Norton L},
  year = {2022},
  journal = {American journal of physiology. Endocrinology and metabolism},
  doi = {10.1152/ajpendo.00050.2022},
  url = {https://doi.org/10.1152/ajpendo.00050.2022}
}

RIS

TY  - JOUR
TI  - FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
AU  - Samms RJ
AU  - Cheng CC
AU  - Fourcaudot M
AU  - Heikkinen S
AU  - Khattab A
AU  - Adams J
AU  - Cersosimo E
AU  - Triplitt C
AU  - Puckett C
AU  - Tsintzas K
AU  - Adams AC
AU  - Abdul-Ghani MA
AU  - DeFronzo RA
AU  - Norton L
PY  - 2022
JO  - American journal of physiology. Endocrinology and metabolism
DO  - 10.1152/ajpendo.00050.2022
UR  - https://doi.org/10.1152/ajpendo.00050.2022
ER  -

APA

RJ, S., CC, C., M, F., S, H., A, K., J, A., E, C., C, T., C, P., K, T., AC, A., MA, A., RA, D., & L, N. (2022). FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.. American journal of physiology. Endocrinology and metabolism. https://doi.org/10.1152/ajpendo.00050.2022

Source records

pubmed · retrieved 2026-09-26T08:36:09.464Z